CDK4/6 Inhibitor Efficacy in <i>ESR1</i> -Mutant Metastatic Breast Cancer
Maxwell R. Lloyd, Jamie O. Brett, Ariel Carmeli, Caroline Weipert, Nicole Zhang, Junhua Yu, Leslie Bucheit, Arielle J. Medford, Nikhil Wagle, Aditya Bardia, Seth A. Wander
Abstract
BACKGROUND: metastatic breast cancer and associated clinical factors. METHODS: ) breast cancer. Data were analyzed to determine the real-world time-to-next-treatment, defined as the start of a breast cancer treatment to initiation of the subsequent treatment. RESULTS: had worse outcomes on ArIh but comparable real-world time-to-next-treatment on fulvestrant. CONCLUSIONS: metastatic breast cancer.
Topics & Concepts
FulvestrantBreast cancerMetastatic breast cancerOncologyInternal medicineMedicineHazard ratioAromatase inhibitorPalbociclibEstrogen receptor alphaCancerEstrogen receptorConfidence intervalTamoxifenAdvanced Breast Cancer TherapiesBRCA gene mutations in cancerBreast Cancer Treatment Studies